P53 Abnormalities and Outcomes in Colorectal Cancer
Author Information
Author(s): Smith F M, Stephens R B, Kennedy M J, Reynolds J V
Primary Institution: University Department of Surgery and The Department of Clinical and Molecular Oncology, St James's Hospital, Dublin 8, Ireland
Hypothesis
Does p53 status predict response to neoadjuvant treatment in rectal cancer?
Conclusion
The study suggests that p53 analysis methods yield unreliable results in predicting treatment response.
Supporting Evidence
- 18 out of 22 studies used immunohistochemistry to assess p53 status.
- Only 4 studies (18%) showed that p53 could predict treatment response.
- No studies using single-strand conformational polymorphism analysis could predict response.
- Both studies using direct p53 gene sequencing indicated that mutations were linked to lower response rates.
Takeaway
Scientists looked at how p53 changes in cancer might affect treatment success, but found the tests used are not very reliable.
Methodology
The analysis included 22 studies assessing p53 status, with various methods like immunohistochemistry and gene sequencing.
Potential Biases
The studies reviewed had varying methodologies and patient treatment protocols, which could introduce bias.
Limitations
The conclusions are based on a limited number of studies and may not be applicable to all treatment types.
Participant Demographics
Patients undergoing neoadjuvant treatment for rectal cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website